Fractyl Health's Revita meets six — month weight — maintenance endpoint in pivotal trial
Fractyl Health reported positive six-month REMAIN-1 results for Revita on October 16, 2026, showing reduced weight regain following GLP-1 discontinuation. The trial met its six-month primary endpoint; no device- or procedure-related serious adverse events were reported. A De Novo marketing application submission to the